Quest Resource Holding's Haystack Technology Powers New HPH MRD Cancer Diagnostic Test

### Advancements in Cancer Diagnostics: HPH MRD Test Launch

The landscape of cancer diagnostics is evolving with the recent launch of the HPH MRD test by MVZ HPH Institute for Pathology and Hematopathology GmbH, based in Hamburg, Germany. This innovative circulating-tumor DNA (ctDNA) blood test is specifically designed to detect minimal residual disease (MRD) in patients with solid tumors. Utilizing Haystack MRD technology, which is licensed from Haystack Oncology, a subsidiary of Quest Diagnostics, the test offers unprecedented sensitivity and specificity in identifying residual or recurrent cancer. This breakthrough not only enhances the clinical utility of diagnostic tools but also underscores the importance of personalized medicine in oncology.

HPH conducts the HPH MRD test in its Hamburg laboratories, which allows for prompt results while adhering to local data protection regulations. Previously, patients requiring similar testing faced delays due to the need for international shipping of samples. This local availability is significant; it streamlines the diagnostic process and ensures that patients receive timely and actionable insights regarding their cancer status. Prof. Markus Tiemann, CEO of HPH, emphasizes the organization's dedication to providing high-quality diagnostic tools that facilitate personalized cancer treatment, ultimately improving patient outcomes.

The introduction of ctDNA MRD testing marks a pivotal advancement in cancer treatment strategies. Unlike traditional imaging methods, which can overlook residual cancer cells, the HPH MRD test identifies tumor-derived DNA fragments circulating in the bloodstream. This capability allows for earlier detection of residual disease, which is crucial in preventing cancer recurrence after surgery and chemotherapy. Dan Edelstein, Vice President & General Manager of Haystack Oncology, highlights the significance of this licensing agreement in expanding access to advanced MRD technologies for European patients and physicians. By empowering clinicians with more accurate diagnostic tools, the HPH MRD test represents a shift towards more proactive and personalized cancer care.

In addition to its innovative technology, the HPH MRD test embodies a commitment to compliance with local regulations, ensuring patient data privacy while delivering critical health insights. As the demand for personalized cancer treatments increases, this test stands as a vital resource in the ongoing battle against cancer, providing both patients and healthcare providers with the necessary tools to make informed treatment decisions.

Overall, the launch of the HPH MRD test signals a significant step forward in the field of oncology, enhancing the capabilities of diagnostic laboratories and improving the quality of care for patients battling solid tumors. With the integration of cutting-edge technology and a focus on timely, individualized patient care, it sets a new standard for cancer diagnostics in Europe and beyond.